摘要
目的观察莫沙必利联合雷贝拉唑治疗胃食管反流病的疗效及对胃肠功能的影响。方法选取2023年1月—2024年1月麻城市人民医院收治的胃食管反流病患者100例为研究对象,根据随机数字表法分为研究组和对照组,每组50例。研究组给予莫沙必利联合雷贝拉唑治疗,对照组给予雷贝拉唑治疗,2组均治疗1个月。比较2组临床疗效,治疗前后食管功能指标[降钙素基因相关肽(CGRP)、内皮素(ET)]、胃肠激素[胃动素(MTL)、胃泌素(GAS)、生长抑素(SS)]、血清炎性因子[白介素-6(IL-6)、降钙素原(PCT)、C反应蛋白(CRP)]、临床症状(反酸、恶心呕吐、胸痛)评分及不良反应。结果研究组总有效率为98.00%,高于对照组的76.00%(χ^(2)=10.698,P=0.001)。治疗1个月后,2组CGRP、MTL、GAS水平高于治疗前,ET、SS、IL-6、PCT、CRP水平均低于治疗前,且研究组高/低于对照组(P<0.01);2组反酸、恶心呕吐、胸痛评分均低于治疗前,且研究组低于对照组(P<0.01)。研究组与对照组不良反应总发生率比较差异无统计学意义(6.00%vs.4.00%,P=1.000)。结论莫沙必利联合雷贝拉唑治疗胃食管反流病的疗效较好,可有效改善患者的胃肠功能和食管功能,减轻体内的炎性反应,缓解临床症状,且安全性较高。
Objective To observe the efficacy of mosapride combined with rabeprazole in the treatment of gastroesophageal reflux disease and its influence on gastrointestinal function.Methods A total of 100 patients with g astroesophageal reflux disease admitted to People′s Hospital of Macheng City from January 2023 to January 2024 were selected as the study objects,and were divided into study group and control group according to random number table method,with 50 patients in each group.The study group was treated with moxapride combined with rabeprazole,the control group was treated with rabeprazole.Both groups were treated for 1 month.The clinical efficacy,esophageal functional indexes(CGRP,ET),g astrointestinal hormones(MTL,GAS,SS),serum inflammatory factors(IL-6,PCT,CRP),clinical symptoms(acid reflux,nausea and vomiting,chest pain)scores before and after treatment,adverse reactions were compared between the two groups.Results The total effective rate of the study group was 98.00%,which was higher than that of the control group(76.00%)(χ^(2)=10.698,P=0.001).After 1 month of treatment,CGRP,MTL and GAS levels in two groups were higher than before treatment,ET,SS,IL-6,PCT and CRP levels were lower than before treatment,and the study group was higher/lower than the control group(P<0.01).The scores of acid reflux,nausea and vomiting and chest pain in two groups were lower than b efore treatment,and the scores in the study group were lower than those in the control group(P<0.01).There was no s ignificant difference in the total incidence of adverse reactions between the study group and the control group(6.00%vs.4.00%,P=1.000).Conclusion Moxapride combined with rabeprazole has good efficacy in the treatment of gastroesophageal reflux disease,which can effectively improve the gastrointestinal function and esophageal function of patients,reduce the i nflammatory response in vivo,relieve clinical symptoms,and have high safety.
作者
陈鲜兰
但昭葵
CHEN Xianlan;DAN Zhaokui(People′s Hospital of Macheng City,Hubei Province,Macheng 438300,China)
出处
《临床合理用药》
2025年第17期16-18,22,共4页
Chinese Journal of Clinical Rational Drug Use
基金
湖北省省级大学生创新创业项目(S202110927027)。
关键词
胃食管反流病
莫沙必利
雷贝拉唑
胃肠功能
Gastroesophageal reflux disease
Moxapride
Rabeprazole
Gastrointestinal function
